TrialNature communications2026

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

Ana C Veneziani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.